Tag

Gilead

MWZB Partner Ryan Pool to speak a AIPLA

We are proud to announce that Ryan Pool has been selected to speak at the AIPLA Mid-Winter Institute IP Practice in Japan Committee Pre-Meeting to be...

A Chipping Away of the Gilead Double Patenting Fiasco

The unorthodox reality presented by the broad Gilead decision in 2014 (Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir. 2014)) is that a patentee obtaining a second...

Are Proactive Portfolio Reviews Needed After 2015 Gilead Double Patenting Decision?

Gilead Sciences, Inc., Hoffmann-La Roche, Inc., F. Hoffmann-La Roche, Ltd., and Genentech, Inc., v.Natco Pharma Ltd.and Natco Pharma, Inc., 753 F.2d 1208 (Fed. Cir. 2014,...

Categories

Archive

MWZB Newsletter Signup

Subscribe
Confidential/Privileged Information MWZB is pleased that you would like to contact the firm. However, you should be aware that any information, documents and the like submitted in connection with this email message or otherwise via the firm’s website will not be treated as a privileged or confidential attorney/client communication unless and until the relationship is governed by an engagement letter. You are not a client of MWZB in the absence of such an engagement letter. If you understand and accept these terms and wish to proceed, please enter your email address below.

Newsletter Signup